The integration of artificial intelligence (AI) in drug discovery is revolutionizing the identification of therapeutic targets and candidates, yet it introduces complexities in resource allocation for these inventions.
Recent insights from a review by Pun et al. in *Nature Reviews Drug Discovery* highlight how AI enhances target identification through innovative techniques like multi-omics integration and knowledge graphs. This expansion necessitates a new framework that incorporates not only traditional scientific criteria but also factors like patentability and market competition during the assessment of drug candidates. The rapid pace of AI-driven discovery creates a challenge: while the number of potential targets is increasing, the decision-making process regarding which candidates to pursue is becoming more intricate.
As AI accelerates the drug discovery timeline, the focus is shifting from merely identifying viable candidates to selecting those that can be effectively validated and advanced. This shift means that teams must now weigh the benefits of scientific novelty against the practicalities of patent protection and market differentiation. For instance, when faced with two promising targets, a team may opt for the one that offers a clearer path to patentability, even if the alternative has stronger initial scientific backing.
This evolving landscape underscores the need for a strategic approach to target selection that balances innovation with the confidence required for successful drug development. By integrating intellectual property considerations early in the process, organizations can make more informed decisions that align with both scientific and commercial objectives, ultimately enhancing the chances of successful therapeutic breakthroughs.